P-Glycoprotein Interactions: Propofol, Fentanyl, and Midazolam (Versed)
Fentanyl is a confirmed P-glycoprotein (P-gp) substrate with clinically significant interactions, while midazolam shows minimal P-gp involvement, and propofol has no established P-gp interaction.
Fentanyl and P-Glycoprotein
Fentanyl demonstrates substantial P-gp substrate activity with critical clinical implications. When P-gp is inhibited, fentanyl brain exposure increases dramatically (2.9-fold increase in unbound brain-to-plasma ratio), leading to prolonged sedation, severe respiratory depression, and potentially fatal outcomes 1. This interaction is particularly dangerous because:
- P-gp normally limits fentanyl penetration across the blood-brain barrier
- Co-administration with P-gp inhibitors (verapamil, diltiazem, erythromycin, ketoconazole) significantly enhances CNS effects 2, 1
- High-dose fentanyl (80 µg/kg) combined with P-gp inhibition resulted in severe respiratory toxicity and death in animal studies 1
Critical clinical caveat: The FDA label for midazolam specifically warns that severe hypotension has occurred in neonates when fentanyl and midazolam are rapidly co-administered, though this appears related to pharmacodynamic synergy rather than P-gp mechanisms 3.
Midazolam (Versed) and P-Glycoprotein
Midazolam shows weak P-gp interaction with minimal clinical relevance. While in vitro studies demonstrate that midazolam can inhibit P-gp-mediated transport of other substrates (like rhodamine 123), P-gp is NOT significantly involved in midazolam's own intestinal transport or clinical pharmacokinetics 4.
The FDA label emphasizes that midazolam's clinically significant interactions occur through CYP3A4 inhibition, not P-gp 3:
- Cimetidine, erythromycin, diltiazem, verapamil, ketoconazole, and itraconazole prolong midazolam sedation by inhibiting hepatic metabolism
- These interactions result in decreased plasma clearance and prolonged half-life (up to 2-fold increase)
Propofol and P-Glycoprotein
No evidence exists for clinically relevant P-gp interactions with propofol. The available literature does not identify propofol as a P-gp substrate, inhibitor, or inducer 5, 6. Propofol's pharmacokinetics and drug interactions occur through different mechanisms (primarily hepatic metabolism and pharmacodynamic synergy with other sedatives).
Clinical Implications for Combined Use
The most critical safety concern when using these agents together relates to pharmacodynamic synergy causing respiratory depression, not P-gp interactions:
The combination of fentanyl and midazolam produces synergistic respiratory depression (92% hypoxemia vs 50% with opioid alone in adult studies), requiring enhanced monitoring and dose reduction 7. This Level B recommendation from emergency medicine guidelines emphasizes:
- Titrate opioids first, then add benzodiazepines 8
- Reduce midazolam dose by 20-50% when combined with fentanyl 9
- Have reversal agents (naloxone, flumazenil) immediately available
- Maintain continuous monitoring with pulse oximetry and capnography
When propofol is added to fentanyl-midazolam combinations, expect:
- Deeper sedation levels 10, 11
- Increased respiratory depression risk 10
- Faster onset but potentially more hemodynamic instability 11
Practical Monitoring Algorithm
When using these agents together:
- Screen for P-gp inhibitors (especially with fentanyl): calcium channel blockers, macrolide antibiotics, azole antifungals
- Reduce fentanyl doses by 25-50% if P-gp inhibitors are present
- Monitor respiratory function aggressively: continuous pulse oximetry, capnography if available
- Titrate slowly: allow 2-5 minutes between doses for peak effect
- Prepare for intervention: have bag-valve-mask, reversal agents, and airway equipment immediately available
The P-gp interaction concern is primarily relevant for fentanyl, not midazolam or propofol, but the pharmacodynamic respiratory depression from combining these agents remains the dominant clinical risk requiring vigilant management.